CDK6 and breast carcinoma: Our findings suggest that the mechanism of CDK4/6 inhibitor resistance exists in multiple forms and that the levels of CDK4 and CDK6 are potential biomarkers of CDK4/6 inhibitors, which may be especially useful for the selection of patients to estimate the sensitivity in breast cancer.